Releases
TYRA
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Tyra Biosciences, Inc. (TYRA) stock and general news. This information may help you make smarter investment decisions.
About TYRA
Tyra Biosciences, Inc. is a precision oncology company. The Company is focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The Company uses its proprietary SNAP platform, which enables refinement of structural design through iterative molecular SNAPshots. The Company is focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR), which are altered in approximately 7% of all cancers. Its lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. In addition, it has pipeline development programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during Transfection kinase (RET), and FGFR4-related cancers.